华北理工大学公共卫生学院;河北省疾病预防控制中心;天津市疾病预防控制中心;
了解河北地区EV-A71(Enterovirus A71)疫苗上市前后EV-A71遗传变异情况。在NCBI网站上获得疫苗株及EV-A71各亚型参考株序列。A亚型参考株为1969年加利福尼亚州分离株，NCBI编号为U22521。B1亚型参考株NCBI编号为AF135871;B2亚型参考株为AF009534;B3亚型参考株为AF376105;B4亚型参考株为AF376111;B5亚型参考株为AY258307;C1亚型参考株为AF376081;C2亚型参考株为AB213614;C3亚型参考株为AY125966;C4a亚型参考株为EU024958/AY905614;C4b亚型参考株为AY547499/AF302996;C5亚型参考株为EF063152；阜阳株为EU703813；疫苗株为HQ328793/EU812515/JX025561。对2011-2019年手足口病患者样本分离的EV-A71 VP1区核苷酸序列进行测定，对获得的序列进行遗传进化、相似性及位点变异等分析。测序成功的196条VP1区序列均属于EV-A71 C4a亚型，相同年份以及相近年份的分离株在进化树中存在聚集现象，各序列之间相似性较高。中和表位PEP27(site142-156)整体受到负向选择压力作用，其中VP1-145位点常出现VP1-145Q与VP1-145G突变；VP1区序列整体处于负向选择压力中。EV-A71疫苗上市前后河北地区EV-A71 VP1区遗传特征相对稳定，未出现较大的变异。
| 120 | 0 | 50 |
| 下载次数 | 被引频次 | 阅读次数 |
[1] Li ML, Shih SR, Tolbert BS, et al. Enterovirus A71vaccines[J]. Vaccines(Basel), 2021, 9(3):199.DOI:10. 3390/vaccines9030199.
[2] Solomon T, Lewthwaite P, Perera D, et al. Virology,epidemiology, pathogenesis, and control of enterovirus71[J]. Lancet Infect Dis, 2010, 10(11):778-790.DOI:10. 1016/S1473-3099(10)70194-8.
[3] Aw-Yong KL, Sam IC, Koh MT, et al.Immunodominant IgM and IgG epitopes recognized by antibodies induced in enterovirus A71-associated hand,foot and mouth disease patients[J]. PLoS One, 2016,11(11):e0165659. DOI:10. 1371/journal.pone. 0165659.
[4] Foo DGW, Macary PA, Alonso S, et al. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71[J]. Viral Immunol, 2008, 21(2):215-224. DOI:10. 1089/vim. 2007. 0089.
[5] Ye X, Ku Z, Liu Q, et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms[J]. J Virol, 2014, 88(1):72-81. DOI:10. 1128/JVI. 01848-13.
[6] Ang PY, Chong CWH, Alonso S. Viral determinants that drive Enterovirus-A71 fitness and virulence[J].Emerg Microbes Infect, 2021, 10(1):713-724. DOI:10. 1080/22221751. 2021. 1906754.
[7] Lin JY, Kung YA, Shih SR. Antivirals and vaccines for enterovirus A71[J]. J Biomed Sci, 2019, 26(1):65.DOI:10. 1186/s12929-019-0560-7.
[8] Aw-Yong KL, NikNadia NMN, Tan CW, et al.Immune responses against enterovirus A71 infection:implications for vaccine success[J]. Rev Med Virol,2019, 29(5):e2073. DOI:10. 1002/rmv. 2073.
[9] Duan X, Zhang C, Wang X, et al. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in Chengdu, China,2017-2022:a descriptive study[J]. Emerg Microbes Infect, 2022, 11(1):2510-2519. DOI:10. 1080/22221751. 2022. 2125346.
[10]Jiang H, Zhang Z, Rao Q, et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China[J]. Emerg Microbes Infect, 2021, 10(1):619-628. DOI:10. 1080/22221751. 2021. 1899772.
[11]Brown DM, Zhang Y, Scheuermann RH.Epidemiology and sequence-based evolutionary analysis of circulating non-polio enteroviruses[J].Microorganisms, 2020, 8(12):1856. DOI:10. 3390/microorganisms8121856.
[12]何文祥，朱颖，陈炜. EV-A71灭活疫苗上市后福建省手足口病流行病学特征及EV-A71基因特征研究[J].病毒学报，2022, 38(5):1099-1107. DOI:10. 13242/j.cnki. bingduxuebao. 004180.
[13]饶清，龙淑英，何文姬，等.柯萨奇病毒B5的VP1区域基因特征分析及蛋白二级结构预测[J].病毒学报，2021, 37(1):106-114. DOI:10. 13242/j. cnki.bingduxuebao. 003851.
[14]韦欢欢，朱俊萍，何秋水.手足口病主要病原变迁及分子进化研究[J].病毒学报，2020, 36(5):936-945.DOI:10. 13242/j. cnki. bingduxuebao. 003704.
[15]Aswathyraj S, Arunkumar G, Alidjinou EK, et al.Hand, foot and mouth disease(HFMD):emerging epidemiology and the need for a vaccine strategy[J].Med Microbiol Immunol, 2016, 205(5):397-407.DOI:10. 1007/s00430-016-0465-y.
[16]Huang SW, Cheng D, Wang JR. Enterovirus A71:virulence, antigenicity, and genetic evolution over the years[J]. J Biomed Sci, 2019, 26(1):81. DOI:10. 1186/s12929-019-0574-1.
[17]Huang SW, Wang YF, Yu CK, et al. Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement[J]. Virology, 2012,422(1):132-143. DOI:10. 1016/j. virol. 2011. 10. 015.
[18]Wang W, Duo J, Liu J, et al. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice[J]. Microbes Infect, 2011, 13(10):862-870. DOI:10. 1016/j. micinf. 2011. 04. 004.
[19]Zaini Z, McMinn P. A single mutation in capsid protein VP1(Q145E)of a genogroup C4 strain of human enterovirus 71 generates a mouse-virulent phenotype[J]. J Gen Virol, 2012, 93(Pt 9):1935-1940. DOI:10. 1099/vir. 0. 043893-0.
[20]Chang SC, Li WC, Chen GW, et al. Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes[J]. J Med Virol, 2012, 84(6):931-939.DOI:10. 1002/jmv. 23287.
[21]Li R, Zou Q, Chen L, et al. Molecular analysis of virulent determinants of enterovirus 71[J]. PLoS One,2011, 6(10):e26237. DOI:10. 1371/journal.pone. 0026237.
[22]Liu Y, Fu C, Wu S, et al. A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in China's mainland[J]. Virus Genes,2014, 48(2):260-272. DOI:10. 1007/s11262-014-1035-2.
[23]Zhang B, Wu X, Huang K, et al. The variations of VP1 protein might be associated with nervous system symptoms caused by enterovirus 71 infection[J]. BMC Infect Dis, 2014, 14:243. DOI:10. 1186/1471-2334-14-243.
[24]肖金波，史景红，严冬梅，等.肠道病毒71型灭活疫苗研究进展[J].中国疫苗和免疫，2024, 30(4):492-500. DOI:10. 19914/j. CJVI. 2024081.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.250001
中图分类号:R373.2
引用信息:
[1]王泽宇,刘莹莹,赵文娜等.EV-A71疫苗上市前后河北地区EV-A71流行株VP1区基因特征分析[J].病毒学报,2025,41(02):310-316.DOI:10.13242/j.cnki.bingduxuebao.250001.
基金信息:
河北省医学科学研究课题（项目号：20231181）,题目：应用EV-A71疫苗前后河北省手足口病流行特征研究~~